Medicines Formulary

Medicines A–Z

B

Drug name	NICE TAs	Comments
Brodalumab (Kyntheum®)	TA511 - Brodalumab for treating moderate to severe plaque psoriasis
Brolucizumab (Beovu®)	TA672 - Brolucizumab for treating wet age-related macular degeneration
Bromocriptine tablets
Bromonidine eye drops		Specialist ophthalmologist recommendation
Budenoside and Formoterol (Symbicort)	TA138 - Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over	For asthma only. Non-formulary for COPD.
Budenoside nebulised
Budesonide 1mg orodispersible tablets (Jorveza®)	TA708 - Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
Budesonide 2mg rectal foam (2mg per 1 metered dose) (Budenofalk®)		Approved to support the shortage of Colifoam (June 2018)
Budesonide 9mg prolonged-release tablets (Cortiment®)
Budesonide capsules (Budenofalk capsules 3mg)		Consultant initiation only

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.